Keyphrases
Adverse Effects
33%
Anticancer Drug Combinations
33%
Anticancer Drugs
33%
Anticancer Treatment
33%
Apoptosis
66%
Apoptosis Imaging
33%
Binding Affinity
33%
Cell Death
33%
Clearance Kinetics
33%
Clinically Significant
33%
Combination Treatment
33%
Dead Cells
33%
Doxorubicin
33%
Drug Combination
33%
Drug Tolerance
33%
Duramycin
66%
Dying Cells
33%
Existing Drugs
33%
Imaging Agents
33%
Imaging Applications
33%
Multi-organ
33%
Multiple Tissues
33%
New Anticancer Drugs
33%
New Combination
33%
New Drug Candidate
33%
Oncology Patients
33%
Organ Index
33%
Pharmaceutical Development
33%
Phosphatidylethanolamine
33%
Prognostic Indicator
33%
Radiopharmaceuticals
33%
Systemic Toxicity
100%
Therapeutic Regimen
66%
Therapy Optimization
33%
Tissue Injury
100%
Toxicity Evaluation
33%
Toxicity Profile
100%
Tumor Cells
33%
Whole-body
100%
Whole-body Imaging
33%
Whole-body Scan
33%
Medicine and Dentistry
Adverse Event
33%
Anticarcinogen
66%
Antiinfective Agent
33%
Binding Affinity
33%
Cell Death
33%
Combination Drug
33%
Diagnosis
33%
Doxorubicin
33%
Drug Tolerance
33%
Imaging Agent
33%
Lancovutide
66%
Oncology
33%
Phosphatidylethanolamine
33%
Programmed Cell Death
100%
Radiopharmaceutical Agent
33%
Technetium-99
66%
Tissue Injury
100%
Tumor Cell
33%
Whole Body Imaging
33%
Whole Body Scintiscanning
33%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
33%
Anticarcinogen
66%
Antiinfective Agent
33%
Combination Drug
33%
Doxorubicin
33%
Drug Tolerability
33%
Lancovutide
66%
Neoplasm
33%
Phosphatidylethanolamine
33%
Radiopharmaceutical Agent
33%
Technetium 99m
66%
Tissue Injury
100%